期刊文献+

HPLC法测定安立生坦原料药中有关物质 被引量:3

Determination of related substances in ambrisentan active pharmaceutical ingredients
原文传递
导出
摘要 目的建立安立生坦原料药中有关物质的测定方法。方法采用HPLC法。Waters Atlantis T3色谱柱(250 mm×4.6mm,5μm);以0.02%三氟乙酸水溶液–0.01%三氟乙酸乙腈溶液为流动相,进行梯度洗脱;柱温30℃;体积流量1.0 m L/min;自动进样器控温5℃;检测波长220 nm。结果安立生坦与各杂质的分离度良好,杂质Z1、Z2、Z3、Z4、DP1的定量限分别为2.14、2.54、2.44、2.45、2.41 ng,平均回收率分别为102.9%、96.0%、93.1%、104.6%、115.2%,RSD值分别为2.1%、4.6%、2.9%、2.7%、4.9%(n=10)。结论该方法检测灵敏度高,精密度好,可以用于安立生坦原料药中有关物质的质量控制。 Objective To establish a method for determination of related substances in ambrisentan active pharmaceutical ingredients. Methods HPLC method was adopted. The determination was performed on Waters Atlantis T3 column(250 mm × 4.6 mm, 5 μm) with mobile phase consisted of 0.02% trifluoroacetic acid- acetonitrile(containing 0.01% trifluoroacetic acid) with gradient elution. The temperature of column was set at 30 ℃. The flow rate was 1.0 mL/min with automatic injection volume of 5 μL. The detective wavelength was set at 220 nm. Results Ambrisentan and its related substances could be separated completely. The LOQ of the related substances, such as Z1, Z2, Z3, Z4, and DP1 were 2.14, 2.54, 2.44, 2.45, and 2.41 ng, respectively. They all had good linearity. The average recovery were 102.9%, 96.0%, 93.1%, 104.6%, and 115.2% with RSD values of 2.1%, 4.6%, 2.9%, 2.7%, and 4.9%(n = 10), respectively. Conclusion The method is sensitive and accurate, and can be used for quality control of related substances in ambrisentan active pharmaceutical ingredients.
出处 《现代药物与临床》 CAS 2015年第2期149-152,共4页 Drugs & Clinic
关键词 安立生坦 有关物质 高效液相色谱 ambrisentan related substances HPLC
  • 相关文献

参考文献4

  • 1Vatter H, Seifert V. Ambrisentan, a non-peptide endothelin receptor antagonist [J]. Cardiovasc Drug Rev, 2006, 24(1): 63-76.
  • 2Frampton J E. Ambrisentan [J]. Am J Cardiovasc Drugs, 2011, 11(4): 215-226.
  • 3国家食品药品监督管理局.安立生坦片进口药品注册标准JX20090317[S].2010.
  • 4Narayana M B, Chandrasekhar K B, Rao B M. A validated specific stability-indicating RP-HPLC assay method for ambrisentan and its related substances [J]. J Chromatogr Sci, 2014, 52(8): 818-825.

同被引文献22

  • 1H·里彻尔斯,D·克林吉,W·埃姆伯格,等.新的羧酸衍生物,其制备和应用[P],中国:1160396,1997-09-24.
  • 2E·鲍曼,J·莱恩海默,U·J·沃格尔巴彻,等.3-(杂)芳基羧酸衍生物,其制备和中间体[P].中国:1121711,1996-05-01.
  • 3H·里彻尔斯,D·克林吉,W·埃姆伯格,等.新的羧酸衍生物,其制备和应用[P].中国:1923820,2007-03-07.
  • 4H·里彻尔斯,D·克林吉,W·埃姆伯格,等.新的羧酸衍生物,其制备和应用[P].中国:1513844,2004-07-21.
  • 5Riechers H,Albrecht H P,Amberg W,et al.Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists[J].J Med Chem,1996,39(11):2123-2128.
  • 6H·博纳德,H·理查斯.2-羟基丙酸类消旋物的拆分[P].中国:1325375,2001-12-05.
  • 7刘文芳,傅得兴,胡欣.治疗肺动脉高压新药安贝生坦的药理与临床研究[J].中国新药杂志,2008,17(23):2070-2073. 被引量:6
  • 8马建芳,张帆,林克江,尤启冬.安贝生坦:新型治疗肺动脉高压的选择性内皮素A受体拮抗药[J].中国新药与临床杂志,2009,28(9):641-644. 被引量:2
  • 9周付刚,谷建敏,苏信杰,邢松松,杜玉民.安贝生坦的合成[J].中国医药工业杂志,2010,41(1):1-3. 被引量:11
  • 10彭婕.安贝生坦研究进展[J].医药导报,2010,29(5):640-643. 被引量:5

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部